OKUR

Onkure Therapeutics, Inc. (OKUR) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Onkure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting vascular anomalies and cancers, specifically utilizing PI3Kα inhibitors. The company operates as a single segment (clinical research) and has no approved products or product revenue. Following a reverse recapitalization merger with Reneo Pharmaceuticals in October 2024, the company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Improvement: Cash and cash equivalents increased significantly from $59.1 million at December 31, 2025, to $192.1 million at March 31, 2026. This was driven by the closing of a 2026 Private Placement on March 31, 2026, which generated approximately $150.0 million in gross proceeds.
• Capital Structure: The company issued 26,713,638 shares of Class A Common Stock and pre-funded warrants to purchase 9,430,957 shares in the Private Placement. Total shares outstanding increased from 13.7 million to 40.4 million.
• Expense Reduction: Total operating expenses decreased by $1.4 million (8.2%) compared to Q1 2025. R&D expenses declined by $1.3 million, primarily due to reduced outsourced R&D costs, partially offset by increased clinical trial costs. G&A expenses remained relatively flat.
• Interest Income: Interest income decreased to $0.5 million from $1.1 million in the prior year quarter, attributed to lower average cash balances available for investment during the early part of the quarter prior to the financing close.

Guidance, Outlook, and Risks

• Going Concern: Management previously expressed substantial doubt about the company's ability to continue as a going concern as of December 31, 2025. Following the 2026 Private Placement, management believes cash resources are sufficient to fund operations for at least the next 12 months, alleviating this doubt.
• Development Pipeline:
  • OKI-219: The PIKture-01 Phase 1a/1b trial has completed dose escalation. The company does not plan to pursue further independent clinical development of OKI-219 given the progress of next-generation candidates.
  • OKI-345 & OKI-355: These next-generation PI3Kα pan-mutant programs (for breast cancer and vascular anomalies) are the primary focus. The company plans to submit Investigational New Drug (IND) applications for both in the first half of 2027.
• Use of Proceeds: Proceeds from the 2026 Private Placement are restricted for R&D expenses related to vascular anomalies and breast cancer programs (excluding OKI-219) and working capital.
• Legal Proceedings: Two shareholder complaints regarding the 2024 Merger remain pending in New York Supreme Court. Plaintiffs have not pursued claims recently, but the company intends to defend vigorously.
• Regulatory Risks: The filing highlights risks related to FDA policy changes under the current administration, potential staffing shortages at the FDA, and the impact of new tariffs on pharmaceutical imports.

Investor Verification Checklist

• Capital Runway: Verify the specific burn rate and confirm the 12-month liquidity runway assertion given the high cash balance post-financing.
• OKI-219 Strategy: Confirm the strategic rationale for halting independent development of OKI-219 and the specific timeline for transitioning resources to OKI-345 and OKI-355.
• Private Placement Terms: Review the lock-up provisions (180 days) and the specific restrictions on the use of proceeds (exclusion of OKI-219 funding).
• Legal Status: Monitor the status of the pending Merger-related litigation (Thomas v. Reneo and Kent v. Reneo) for any new activity.
• Regulatory Timeline: Track the progress toward the planned H1 2027 IND submissions for OKI-345 and OKI-355.